Analytical Performance of Next-Generation Sequencing and RT-PCR on Formalin-Fixed Paraffin-Embedded Tumor Tissues for PIK3CA Testing in HR+/HER2- Breast Cancer.
Cells
Venetis, Konstantinos K; Pepe, Francesco F; Munzone, Elisabetta E; Sajjadi, Elham E; Russo, Gianluca G; Pisapia, Pasquale P; Ivanova, Mariia M; Bonizzi, Giuseppina G; Vacirca, Davide D; Rappa, Alessandra A; Ranghiero, Alberto A; Taormina, Sergio Vincenzo SV; Viale, Giuseppe G; Troncone, Giancarlo G; Barberis, Massimo M; Guerini-Rocco, Elena E; Malapelle, Umberto U; Fusco, Nicola N
Scalable multiplex co-fractionation/mass spectrometry platform for accelerated protein interactome discovery.
Nature Communications
Havugimana, Pierre C PC; Goel, Raghuveera Kumar RK; Phanse, Sadhna S; Youssef, Ahmed A; Padhorny, Dzmitry D; Kotelnikov, Sergei S; Kozakov, Dima D; Emili, Andrew A
Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status.
Cancers
Irelli, Azzurra A; Parisi, Alessandro A; D'Orazio, Carla C; Sidoni, Tina T; Rotondaro, Silvia S; Patruno, Leonardo L; Pavese, Francesco F; Bafile, Alberto A; Resta, Valter V; Pizzorno, Laura L; Ciuffetelli, Virginia V; Dal Mas, Antonella A; Calvisi, Giuseppe G; Di Sibio, Alessandra A; Marzullo, Anna A; Zelli, Veronica V; Compagnoni, Chiara C; Tessitore, Alessandra A; Alesse, Edoardo E; Ficorella, Corrado C; Cortellini, Alessio A; Cannita, Katia K
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.
The Lancet. Oncology
Howell, Sacha J SJ; Casbard, Angela A; Carucci, Margherita M; Ingarfield, Kate K; Butler, Rachel R; Morgan, Sian S; Meissner, Magdalena M; Bale, Catherine C; Bezecny, Pavel P; Moon, Sarah S; Twelves, Chris C; Venkitaraman, Ramachandran R; Waters, Simon S; de Bruin, Elza C EC; Schiavon, Gaia G; Foxley, Andrew A; Jones, Robert H RH
Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations.
Investigational New Drugs
Lee, Jii Bum JB; Jung, Minkyu M; Beom, Seung Hoon SH; Kim, Gun Min GM; Kim, Hye Ryun HR; Choi, Hye Jin HJ; Sohn, Joo Hyuk JH; Ahn, Joong Bae JB; Rha, Sun Young SY; Chung, Hyun Cheol HC
Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008).
Gynecologic Oncology Reports
Santin, Alessandro D AD; Filiaci, Virginia V; Bellone, Stefania S; Ratner, Elena S ES; Mathews, Cara A CA; Cantuaria, Guilherme G; Gunderson, Camille C CC; Rutledge, Teresa T; Buttin, Barbara M BM; Lankes, Heather A HA; Frumovitz, Michael M; Khleif, Samir N SN; Huh, Warner K WK; Birrer, Michael J MJ
A comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of novel loss-of-function variants.
Scientific Reports
Ticha, Ivana I; Hojny, Jan J; Michalkova, Romana R; Kodet, Ondrej O; Krkavcova, Eva E; Hajkova, Nikola N; Nemejcova, Kristyna K; Bartu, Michaela M; Jaksa, Radek R; Dura, Miroslav M; Kanwal, Madiha M; Martinikova, Andra S AS; Macurek, Libor L; Zemankova, Petra P; Kleibl, Zdenek Z; Dundr, Pavel P
Base excision repair deficiency signatures implicate germline and somatic MUTYH aberrations in pancreatic ductal adenocarcinoma and breast cancer oncogenesis.
Cold Spring Harbor Molecular Case Studies
Thibodeau, My Linh ML; Zhao, Eric Y EY; Reisle, Caralyn C; Ch'ng, Carolyn C; Wong, Hui-Li HL; Shen, Yaoqing Y; Jones, Martin R MR; Lim, Howard J HJ; Young, Sean S; Cremin, Carol C; Pleasance, Erin E; Zhang, Wei W; Holt, Robert R; Eirew, Peter P; Karasinska, Joanna J; Kalloger, Steve E SE; Taylor, Greg G; Majounie, Elisa E; Bonakdar, Melika M; Zong, Zusheng Z; Bleile, Dustin D; Chiu, Readman R; Birol, Inanc I; Gelmon, Karen K; Lohrisch, Caroline C; Mungall, Karen L KL; Mungall, Andrew J AJ; Moore, Richard R; Ma, Yussanne P YP; Fok, Alexandra A; Yip, Stephen S; Karsan, Aly A; Huntsman, David D; Schaeffer, David F DF; Laskin, Janessa J; Marra, Marco A MA; Renouf, Daniel J DJ; Jones, Steven J M SJM; Schrader, Kasmintan A KA
Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.
Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research
Dickler, Maura N MN; Saura, Cristina C; Richards, Donald A DA; Krop, Ian E IE; Cervantes, Andrés A; Bedard, Philippe L PL; Patel, Manish R MR; Pusztai, Lajos L; Oliveira, Mafalda M; Cardenas, Alison K AK; Cui, Na N; Wilson, Timothy R TR; Stout, Thomas J TJ; Wei, Michael C MC; Hsu, Jerry Y JY; Baselga, José J
PIK3CA mutation, reduced AKT serine 473 phosphorylation, and increased ERα serine 167 phosphorylation are positive prognostic indicators in postmenopausal estrogen receptor-positive early breast cancer.
Oncotarget
Ishida, Naoko N; Baba, Motoi M; Hatanaka, Yutaka Y; Hagio, Kanako K; Okada, Hiromi H; Hatanaka, Kanako C KC; Togashi, Kenichi K; Matsuno, Yoshihiro Y; Yamashita, Hiroko H
Formalin fixation increases deamination mutation signature but should not lead to false positive mutations in clinical practice.
Plos One
Prentice, Leah M LM; Miller, Ruth R RR; Knaggs, Jeff J; Mazloomian, Alborz A; Aguirre Hernandez, Rosalia R; Franchini, Patrick P; Parsa, Kourosh K; Tessier-Cloutier, Basile B; Lapuk, Anna A; Huntsman, David D; Schaeffer, David F DF; Sheffield, Brandon S BS
PIK3CA mutations are associated with increased tumor aggressiveness and Akt activation in gastric cancer.
Oncotarget
Kim, Ji-Won JW; Lee, Hye Seung HS; Nam, Kyung Han KH; Ahn, Soyeon S; Kim, Jin Won JW; Ahn, Sang-Hoon SH; Park, Do Joong DJ; Kim, Hyung-Ho HH; Lee, Keun-Wook KW
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
The Lancet. Oncology
Kim, Sung-Bae SB; Dent, Rebecca R; Im, Seock-Ah SA; Espié, Marc M; Blau, Sibel S; Tan, Antoinette R AR; Isakoff, Steven J SJ; Oliveira, Mafalda M; Saura, Cristina C; Wongchenko, Matthew J MJ; Kapp, Amy V AV; Chan, Wai Y WY; Singel, Stina M SM; Maslyar, Daniel J DJ; Baselga, José J; ,
Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging.
Bmc Cancer
García-Saenz, José Angel JA; Ayllón, Patricia P; Laig, Marion M; Acosta-Eyzaguirre, Daniel D; García-Esquinas, Marta M; Montes, Myriam M; Sanz, Julián J; Barquín, Miguel M; Moreno, Fernando F; Garcia-Barberan, Vanesa V; Díaz-Rubio, Eduardo E; Caldes, Trinidad T; Romero, Atocha A
Amplicon sequencing of colorectal cancer: variant calling in frozen and formalin-fixed samples.
Plos One
Betge, Johannes J; Kerr, Grainne G; Miersch, Thilo T; Leible, Svenja S; Erdmann, Gerrit G; Galata, Christian L CL; Zhan, Tianzuo T; Gaiser, Timo T; Post, Stefan S; Ebert, Matthias P MP; Horisberger, Karoline K; Boutros, Michael M